DENVER / May 04, 2023 / Business Wire / Modivcare Inc., (the “Company” or “Modivcare”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving patient outcomes, today reported financial results for the three months ended March 31, 2023.
First Quarter 2023 Highlights:
(1) Non-GAAP financial measure reconciliations and other related information about non-GAAP financial measures provided below |
“We reported solid first quarter results with 15 percent revenue growth driven by strong growth across each of our segments,” said L. Heath Sampson, President and Chief Executive Officer. “We remain confident in our 2023 outlook, which we maintained, due to several factors, including recent new contract wins, a strong pipeline for new business, and the continued success of our Home business. As the U.S. healthcare system increasingly shifts to home-based care, we are well positioned to capitalize on these opportunities with our supportive care services. Our offerings provide high quality care and services to our members in a cost-effective manner, aligning with the evolving needs of the healthcare landscape. Our focus for 2023 remains steadfast to build for scale and grow our business. We are confident that the initiatives implemented over the past few quarters will drive efficiencies and operating leverage throughout the year. I am incredibly proud of our team’s ability to perform and execute at a high level, and I am grateful for their hard work and dedication.”
2023 Guidance
We maintained our 2023 revenue and our Adjusted EBITDA guidance range as follows ($ in millions):
| Low | High | |||||||||
Revenue | $ | 2,575 | $ | 2,600 | |||||||
Adjusted EBITDA | $ | 225 | $ | 235 |
Guidance excludes the effects of any future merger or acquisition activity and is based on the current operating environment.
First Quarter 2023 Results
For the first quarter of 2023, the Company reported revenue of $662.3 million, an increase of 15.3% from $574.5 million in the first quarter of 2022. The increase in revenue is primarily attributable to a 4.7% increase in membership and an 11.8% increase in revenue per member in our NEMT segment coupled with a 4.4% increase in hours worked and a 4.4% increase in rate per hour in our personal care segment.
Operating income was $8.1 million, or 1.2% of revenue, in the first quarter of 2023, compared to operating income of $14.9 million, or 2.6% of revenue, in the first quarter of 2022. Net loss in the first quarter of 2023 was $4.0 million, or $0.28 per diluted common share, compared to net income of $0.3 million, or $0.02 per diluted common share, in the first quarter of 2022.
Adjusted EBITDA was $50.2 million, or 7.6% of revenue, in the first quarter of 2023, compared to $50.3 million, or 8.8% of revenue, in the first quarter of 2022.
Adjusted net income in the first quarter of 2023 was $20.2 million, or $1.42 per diluted common share, compared to $22.2 million, or $1.57 per diluted common share, in the first quarter of 2022.
First Quarter Earnings Conference Call
Modivcare will hold a conference call to discuss its financial results on Thursday, May 4, 2023 at 8:00 a.m. ET. To access the call, please dial:
US toll-free: 1 (888) 437-3179
International: 1 (862) 298-0702
You may also access the conference call via webcast at investors.modivcare.com, where the call will also be archived.
About Modivcare
Modivcare Inc. (Nasdaq: MODV) is a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions for public and private payors and their patients. Our value-based solutions are intended to address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation (NEMT), personal care and remote patient monitoring. To learn more about Modivcare, please visit www.modivcare.com.
Non-GAAP Financial Measures and Adjustments
In addition to the financial measures prepared in accordance with generally accepted accounting principles in the United States ("GAAP"), this press release includes EBITDA, Adjusted EBITDA and Adjusted G&A expense for the Company and its segments, Adjusted EBITDA margin for the Company's segments (other than its Corporate segment), and Adjusted Net Income and Adjusted EPS for the Company, all of which are performance measures that are not recognized under GAAP. EBITDA is defined as net income (loss) before: (1) interest expense, net, (2) provision (benefit) for income taxes and (3) depreciation and amortization. Adjusted EBITDA is calculated as EBITDA before (as applicable): (1) restructuring and related costs, including severance and organizational consolidation costs and professional services fees, (2) certain transaction and integration costs, (3) settlement related costs, (4) cash settled equity, (5) stock-based compensation, (6) COVID-19 related costs, net of grant income, and (7) equity in net (income) loss of investee, net of tax. Adjusted EBITDA margin is calculated as Adjusted EBITDA, divided by service revenue, net. Adjusted Net Income is calculated as net income (loss) before: (1) restructuring and related costs, including severance and organizational consolidation costs and professional services fees (2) certain transaction and integration costs, (3) settlement related costs, (4) cash settled equity, (5) stock-based compensation, (6) equity in net (income) loss of investee, net of tax (7) intangible amortization expense, (8) COVID-19 related costs, net of grant income, and (9) the income tax impact of such adjustments. Adjusted EPS is calculated as Adjusted Net Income divided by the diluted weighted-average number of common shares outstanding as calculated for Adjusted Net Income. Adjusted G&A expense is calculated as G&A expense before (as applicable): (1) restructuring and related costs, (2) transaction and integration costs, (3) settlement related costs, (4) cash settled equity, and (5) stock-based compensation. We do not provide guidance for net income (loss) in this presentation on a basis consistent with GAAP or a reconciliation of forward-looking non-GAAP financial measures to their most directly comparable GAAP financial measures on a forward-looking basis because we are unable to predict items contained in the GAAP financial measures without unreasonable efforts. Our non-GAAP performance measures exclude expenses and amounts that are not driven by our core operating results and may be one time in nature. Excluding these expenses makes comparisons with prior periods as well as to other companies in our industry more meaningful. We believe such measures allow investors to gain a better understanding of the factors and trends affecting the ongoing operations of our business. We consider our core operations to be the ongoing activities to provide services from which we earn revenue, including direct operating costs and indirect costs to support these activities. As a result, our net income or loss in equity investee is excluded from these measures, as we do not have the ability to manage the venture, allocate resources within the venture, or directly control its operations or performance.
Our non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in our industry, as other companies in our industry may calculate non-GAAP financial measures differently. In addition, there are limitations in using non-GAAP financial measures because they are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies, and exclude expenses that may have a material impact on our reported financial results. The presentation of non-GAAP financial measures is not intended to be considered in isolation from or as a substitute for the most directly comparable financial measures prepared in accordance with GAAP. We urge you to review the reconciliations of our non-GAAP financial measures to the most directly comparable GAAP financial measures included below, and not to rely on any single financial measure to evaluate our business.
Forward-Looking Statements
Certain statements contained in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictive in nature and are frequently identified by the use of terms such as “may,” “will,” “should,” “expect,” “believe,” “estimate,” “intend,” and similar words indicating possible future expectations, events or actions. The updated guidance discussed herein constitutes forward-looking statements. Such forward-looking statements are based on current expectations, assumptions, estimates and projections about our business and our industry, and are not guarantees of our future performance. These statements are subject to a number of known and unknown risks, uncertainties and other factors, many of which are beyond our ability to control or predict, which may cause actual events to be materially different from those expressed or implied herein, including but not limited to: government or private insurance program funding reductions or limitations; alternative payment models or the transition of Medicaid and Medicare beneficiaries to Managed Care Organizations, or MCOs; our inability to control reimbursement rates received for our services; cost containment initiatives undertaken by private third-party payors; the effects of a public health emergency; inadequacies in, or security breaches of, our information technology systems, including the systems intended to protect our clients’ privacy and confidential information; any changes in the funding, financial viability or our relationships with our payors; pandemic infectious diseases, including the COVID-19 pandemic; disruptions to our contact center operations caused by health epidemics or pandemics like COVID-19; delays in collection, or non-collection, of our accounts receivable, particularly during any business integration; an impairment of our goodwill and long-lived assets; any failure to maintain or to develop reliable, efficient and secure information technology systems; an inability to attract and retain qualified employees; any acquisition or acquisition integration efforts; estimated income taxes being different from income taxes that we ultimately pay; our contracts not surviving until the end of their stated terms, or not being renewed or extended; our failure to compete effectively in the marketplace; our not being awarded contracts through the government’s requests for proposals process, or our awarded contracts not being profitable; any failure to satisfy our contractual obligations or to maintain existing pledged performance and payment bonds; a failure to estimate accurately the cost of performing our contracts; any misclassification of the drivers we engage as independent contractors rather than as employees; significant interruptions in our communication and data services; not successfully executing on our strategies in the face of our competition; any inability to maintain relationships with existing patient referral sources; certificates of need, or CON, laws or other regulatory and licensure obligations that may adversely affect our personal care integration efforts and expansion into new markets; any failure to obtain the consent of the New York Department of Health to manage the day to day operations of our licensed in-home personal care services agency business that we acquired with our personal care segment; changes in the case-mix of our personal care patients, or changes in payor mix or payment methodologies; our loss of existing favorable managed care contracts; our experiencing labor shortages in qualified employees and management; labor disputes or disruptions, in particular in New York; becoming subject to malpractice or other similar claims; our operating in the competitive remote patient monitoring industry, and failing to develop and enhance related technology applications; any failure to innovate and provide services that are useful to customers and to achieve and maintain market acceptance; and our lack of sole decision-making authority with respect to our minority investment in Matrix and any failure by Matrix to achieve positive financial results of operations.
The Company has provided additional information about the risks facing our business in our annual report on Form 10-K and subsequent periodic and current reports most recently filed with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made and are expressly qualified in their entirety by the cautionary statements set forth herein and in our filings with the Securities and Exchange Commission, which you should read in their entirety before making an investment decision with respect to our securities. We undertake no obligation to update or revise any forward-looking statements contained in this release, whether as a result of new information, future events or otherwise, except as required by applicable law.
Modivcare Inc. | ||||||||
Unaudited Condensed Consolidated Statements of Operations | ||||||||
(in thousands, except share and per share data) | ||||||||
|
|
|
|
| ||||
|
| Three months ended March 31, | ||||||
|
|
| 2023 |
|
|
| 2022 |
|
|
|
|
|
| ||||
Service revenue, net |
| $ | 662,306 |
|
| $ | 574,475 |
|
Grant income |
|
| 1,464 |
|
|
| 468 |
|
|
|
|
|
| ||||
Operating expenses: |
|
|
|
| ||||
Service expense |
|
| 550,266 |
|
|
| 459,315 |
|
General and administrative expense |
|
| 79,713 |
|
|
| 76,808 |
|
Depreciation and amortization |
|
| 25,693 |
|
|
| 23,946 |
|
Total operating expenses |
|
| 655,672 |
|
|
| 560,069 |
|
|
|
|
|
| ||||
Operating income |
|
| 8,098 |
|
|
| 14,874 |
|
|
|
|
|
| ||||
Interest expense, net |
|
| 15,958 |
|
|
| 15,400 |
|
Loss before income taxes and equity method investment |
|
| (7,860 | ) |
|
| (526 | ) |
Benefit for income taxes |
|
| (1,873 | ) |
|
| (361 | ) |
Equity in net income of investee, net of tax |
|
| (2,025 | ) |
|
| (483 | ) |
Net income (loss) |
| $ | (3,962 | ) |
| $ | 318 |
|
|
|
|
|
| ||||
Earnings (loss) per common share: |
|
|
|
| ||||
Basic |
| $ | (0.28 | ) |
| $ | 0.02 |
|
Diluted |
| $ | (0.28 | ) |
| $ | 0.02 |
|
|
|
|
|
| ||||
Weighted-average number of common shares outstanding: |
|
| ||||||
Basic |
|
| 14,163,511 |
|
|
| 14,023,585 |
|
Diluted |
|
| 14,163,511 |
|
|
| 14,123,825 |
|
Modivcare Inc. | ||||||
Unaudited Condensed Consolidated Balance Sheets | ||||||
(in thousands) | ||||||
|
|
|
|
| ||
|
| March 31, 2023 |
| December 31, 2022 | ||
Assets |
|
|
|
| ||
Current assets: |
|
|
|
| ||
Cash and cash equivalents |
| $ | 12,848 |
| $ | 14,451 |
Accounts receivable, net |
|
| 296,745 |
|
| 294,341 |
Other current assets(1) |
|
| 38,638 |
|
| 37,362 |
Total current assets |
|
| 348,231 |
|
| 346,154 |
Property and equipment, net |
|
| 76,252 |
|
| 69,138 |
Goodwill and intangible assets, net |
|
| 1,388,576 |
|
| 1,408,063 |
Equity investment |
|
| 43,698 |
|
| 41,303 |
Operating lease right-of-use assets |
|
| 40,311 |
|
| 39,405 |
Other long-term assets |
|
| 44,461 |
|
| 40,209 |
Total assets |
| $ | 1,941,529 |
| $ | 1,944,272 |
|
|
|
|
| ||
Liabilities and stockholders' equity | ||||||
Current liabilities: |
|
|
|
| ||
Short-term borrowings |
| $ | 15,000 |
| $ | — |
Accounts payable |
|
| 54,987 |
|
| 54,959 |
Accrued contract payables |
|
| 187,620 |
|
| 194,287 |
Accrued expenses and other current liabilities |
|
| 132,978 |
|
| 135,860 |
Accrued transportation costs |
|
| 93,726 |
|
| 96,851 |
Current portion of operating lease liabilities |
|
| 9,852 |
|
| 9,640 |
Total current liabilities |
|
| 494,163 |
|
| 491,597 |
Long-term debt, net of deferred financing costs |
|
| 980,433 |
|
| 979,361 |
Operating lease liabilities, less current portion |
|
| 32,867 |
|
| 32,088 |
Other long-term liabilities(2) |
|
| 82,968 |
|
| 86,670 |
Total liabilities |
|
| 1,590,431 |
|
| 1,589,716 |
|
|
|
|
| ||
Stockholders' equity |
|
|
|
| ||
Stockholders' equity |
|
| 351,098 |
|
| 354,556 |
Total liabilities and stockholders' equity |
| $ | 1,941,529 |
| $ | 1,944,272 |
(1) Includes other receivables, prepaid expenses and other current assets and short-term restricted cash. | ||||||
(2) Includes other long-term liabilities and deferred tax liabilities. |
Modivcare Inc. | ||||||||
Unaudited Condensed Consolidated Statements of Cash Flows | ||||||||
(in thousands) | ||||||||
|
|
|
|
| ||||
|
| Three months ended March 31, | ||||||
|
|
| 2023 |
|
|
| 2022 |
|
Operating activities |
|
|
|
| ||||
Net income (loss) |
| $ | (3,962 | ) |
| $ | 318 |
|
Depreciation and amortization |
|
| 25,693 |
|
|
| 23,946 |
|
Stock-based compensation |
|
| 1,124 |
|
|
| 2,049 |
|
Equity in net income of investee |
|
| (2,810 | ) |
|
| (671 | ) |
Deferred income taxes |
|
| (3,624 | ) |
|
| (6,587 | ) |
Reduction of right-of-use asset |
|
| 3,547 |
|
|
| 2,884 |
|
Other non-cash items(1) |
|
| (2,975 | ) |
|
| (1,996 | ) |
Changes in working capital(2) |
|
| (19,648 | ) |
|
| 51,542 |
|
Net cash provided by (used in) operating activities |
|
| (2,655 | ) |
|
| 71,485 |
|
|
|
|
|
| ||||
Investing activities |
|
|
|
| ||||
Purchase of property and equipment |
|
| (13,320 | ) |
|
| (8,584 | ) |
Net cash used in investing activities |
|
| (13,320 | ) |
|
| (8,584 | ) |
|
|
|
|
| ||||
Financing activities |
|
|
|
| ||||
Proceeds from short-term borrowings |
|
| 15,000 |
|
|
| — |
|
Debt issuance costs |
|
| — |
|
|
| (2,415 | ) |
Proceeds from common stock issued pursuant to stock option exercise |
|
| — |
|
|
| 1,138 |
|
Restricted stock surrendered for employee tax payment |
|
| (620 | ) |
|
| (572 | ) |
Net cash provided by (used in) financing activities |
|
| 14,380 |
|
|
| (1,849 | ) |
|
|
|
|
| ||||
Net change in cash, cash equivalents and restricted cash |
|
| (1,595 | ) |
|
| 61,052 |
|
Cash, cash equivalents and restricted cash at beginning of period |
|
| 14,975 |
|
|
| 133,422 |
|
Cash, cash equivalents and restricted cash at end of period |
| $ | 13,380 |
|
| $ | 194,474 |
|
(1) Includes provision for doubtful accounts and amortization of deferred financing costs and debt discount. | ||||||||
(2) Includes accounts receivable and other receivables, prepaid expenses and other current assets, accrued contract payables, accounts payable and accrued expenses, accrued transportation costs and other long-term liabilities. |
Modivcare Inc. Unaudited Reconciliation of Non-GAAP Financial Measures Segment Information and Adjusted EBITDA (in thousands) | |||||||||||||||||
| Three months ended March 31, 2023 | ||||||||||||||||
| NEMT |
| Personal Care |
| RPM |
| Corporate |
| Total | ||||||||
|
|
|
|
|
|
|
|
|
| ||||||||
Service revenue, net | $ | 469,463 |
|
| $ | 174,131 |
| $ | 18,712 |
| $ | — |
|
| $ | 662,306 |
|
Grant income |
| — |
|
|
| 1,464 |
|
| — |
|
| — |
|
|
| 1,464 |
|
|
|
|
|
|
|
|
|
|
| ||||||||
Operating expenses: |
|
|
|
|
|
|
|
|
| ||||||||
Service expense |
| 407,686 |
|
|
| 136,090 |
|
| 6,490 |
|
| — |
|
|
| 550,266 |
|
General and administrative expense |
| 33,875 |
|
|
| 22,663 |
|
| 5,769 |
|
| 17,406 |
|
|
| 79,713 |
|
Depreciation and amortization |
| 6,766 |
|
|
| 12,868 |
|
| 5,854 |
|
| 205 |
|
|
| 25,693 |
|
Total operating expenses |
| 448,327 |
|
|
| 171,621 |
|
| 18,113 |
|
| 17,611 |
|
|
| 655,672 |
|
|
|
|
|
|
|
|
|
|
| ||||||||
Operating income (loss) |
| 21,136 |
|
|
| 3,974 |
|
| 599 |
|
| (17,611 | ) |
|
| 8,098 |
|
|
|
|
|
|
|
|
|
|
| ||||||||
Interest expense, net |
| — |
|
|
| — |
|
| — |
|
| 15,958 |
|
|
| 15,958 |
|
Income (loss) before income taxes and equity method investment |
| 21,136 |
|
|
| 3,974 |
|
| 599 |
|
| (33,569 | ) |
|
| (7,860 | ) |
Provision (benefit) for income taxes |
| 5,618 |
|
|
| 1,149 |
|
| 170 |
|
| (8,810 | ) |
|
| (1,873 | ) |
Equity in net income of investee, net of tax |
| (653 | ) |
|
| — |
|
| — |
|
| (1,372 | ) |
|
| (2,025 | ) |
Net income (loss) |
| 16,171 |
|
|
| 2,825 |
|
| 429 |
|
| (23,387 | ) |
|
| (3,962 | ) |
|
|
|
|
|
|
|
|
|
| ||||||||
Interest expense, net |
| — |
|
|
| — |
|
| — |
|
| 15,958 |
|
|
| 15,958 |
|
Provision (benefit) for income taxes |
| 5,618 |
|
|
| 1,149 |
|
| 170 |
|
| (8,810 | ) |
|
| (1,873 | ) |
Depreciation and amortization |
| 6,766 |
|
|
| 12,868 |
|
| 5,854 |
|
| 205 |
|
|
| 25,693 |
|
EBITDA |
| 28,555 |
|
|
| 16,842 |
|
| 6,453 |
|
| (16,034 | ) |
|
| 35,816 |
|
|
|
|
|
|
|
|
|
|
| ||||||||
Restructuring and related costs(1) |
| 7,099 |
|
|
| — |
|
| — |
|
| 7,346 |
|
|
| 14,445 |
|
Transaction and integration costs(2) |
| — |
|
|
| 277 |
|
| 32 |
|
| 564 |
|
|
| 873 |
|
Settlement related costs |
| 275 |
|
|
| — |
|
| — |
|
| — |
|
|
| 275 |
|
Stock-based compensation |
| — |
|
|
| — |
|
| — |
|
| 848 |
|
|
| 848 |
|
Equity in net income of investee, net of tax |
| (653 | ) |
|
| — |
|
| — |
|
| (1,372 | ) |
|
| (2,025 | ) |
|
|
|
|
|
|
|
|
|
| ||||||||
Adjusted EBITDA | $ | 35,276 |
|
| $ | 17,119 |
| $ | 6,485 |
| $ | (8,648 | ) |
| $ | 50,232 |
|
(1) Restructuring and related costs include professional fees for strategic initiatives, organizational consolidation costs, severance and other professional fees. | |||||||||||||||||
(2) Transaction and integration costs consist of fees incurred related to Sarbanes-Oxley Act of 2002 ("SOX") implementation and business integration efforts. |
Modivcare Inc. Unaudited Reconciliation of Non-GAAP Financial Measures Segment Information and Adjusted EBITDA (in thousands) | |||||||||||||||||
| Three months ended March 31, 2022 | ||||||||||||||||
| NEMT |
| Personal Care |
| RPM |
| Corporate |
| Total | ||||||||
|
|
|
|
|
|
|
|
|
| ||||||||
Service revenue, net | $ | 400,920 |
| $ | 159,698 |
| $ | 13,857 |
|
| $ | — |
|
| $ | 574,475 |
|
Grant income |
| — |
|
| 468 |
|
| — |
|
|
| — |
|
|
| 468 |
|
|
|
|
|
|
|
|
|
|
| ||||||||
Operating expenses: |
|
|
|
|
|
|
|
|
| ||||||||
Service expense |
| 332,096 |
|
| 122,232 |
|
| 4,987 |
|
|
| — |
|
|
| 459,315 |
|
General and administrative expense |
| 37,333 |
|
| 23,133 |
|
| 4,962 |
|
|
| 11,380 |
|
|
| 76,808 |
|
Depreciation and amortization |
| 7,105 |
|
| 12,505 |
|
| 4,128 |
|
|
| 208 |
|
|
| 23,946 |
|
Total operating expenses |
| 376,534 |
|
| 157,870 |
|
| 14,077 |
|
|
| 11,588 |
|
|
| 560,069 |
|
|
|
|
|
|
|
|
|
|
| ||||||||
Operating income (loss) |
| 24,386 |
|
| 2,296 |
|
| (220 | ) |
|
| (11,588 | ) |
|
| 14,874 |
|
|
|
|
|
|
|
|
|
|
| ||||||||
Interest expense, net |
| — |
|
| — |
|
| — |
|
|
| 15,400 |
|
|
| 15,400 |
|
Income (loss) before income taxes and equity method investment |
| 24,386 |
|
| 2,296 |
|
| (220 | ) |
|
| (26,988 | ) |
|
| (526 | ) |
Provision (benefit) for income taxes |
| 6,575 |
|
| 640 |
|
| (58 | ) |
|
| (7,518 | ) |
|
| (361 | ) |
Equity in net (income) loss of investee, net of tax |
| 65 |
|
| — |
|
| — |
|
|
| (548 | ) |
|
| (483 | ) |
Net income (loss) |
| 17,746 |
|
| 1,656 |
|
| (162 | ) |
|
| (18,922 | ) |
|
| 318 |
|
|
|
|
|
|
|
|
|
|
| ||||||||
Interest expense, net |
| — |
|
| — |
|
| — |
|
|
| 15,400 |
|
|
| 15,400 |
|
Provision (benefit) for income taxes |
| 6,575 |
|
| 640 |
|
| (58 | ) |
|
| (7,518 | ) |
|
| (361 | ) |
Depreciation and amortization |
| 7,105 |
|
| 12,505 |
|
| 4,128 |
|
|
| 208 |
|
|
| 23,946 |
|
EBITDA |
| 31,426 |
|
| 14,801 |
|
| 3,908 |
|
|
| (10,832 | ) |
|
| 39,303 |
|
|
|
|
|
|
|
|
|
|
| ||||||||
Restructuring and related costs(1) |
| 5,604 |
|
| 181 |
|
| 24 |
|
|
| 31 |
|
|
| 5,840 |
|
Transaction and integration costs(2) |
| — |
|
| 1,273 |
|
| 647 |
|
|
| 1,791 |
|
|
| 3,711 |
|
Cash settled equity |
| — |
|
| — |
|
| — |
|
|
| (13 | ) |
|
| (13 | ) |
Stock-based compensation |
| — |
|
| 17 |
|
| 29 |
|
|
| 1,420 |
|
|
| 1,466 |
|
COVID-19 related costs, net of grant income |
| 122 |
|
| 349 |
|
| — |
|
|
| — |
|
|
| 471 |
|
Equity in net (income) loss of investee, net of tax |
| 65 |
|
| — |
|
| — |
|
|
| (548 | ) |
|
| (483 | ) |
|
|
|
|
|
|
|
|
|
| ||||||||
Adjusted EBITDA | $ | 37,217 |
| $ | 16,621 |
| $ | 4,608 |
|
| $ | (8,151 | ) |
| $ | 50,295 |
|
(1) Restructuring and related costs include professional services costs and severance and recruiting costs. | |||||||||||||||||
(2) Transaction and integration costs include SOX integration efforts at recently acquired subsidiaries and acquisition costs. |
Modivcare Inc. Unaudited Reconciliation of Non-GAAP Financial Measures Adjusted Net Income and Adjusted Net Income per Common Share (in thousands, except share and per share data) | |||||||
| Three months ended March 31, | ||||||
|
| 2023 |
|
|
| 2022 |
|
|
|
|
| ||||
Net income (loss) | $ | (3,962 | ) |
| $ | 318 |
|
|
|
|
| ||||
Restructuring and related costs(1) |
| 14,445 |
|
|
| 5,840 |
|
Transaction and integration costs(2) |
| 873 |
|
|
| 3,711 |
|
Settlement related costs |
| 275 |
|
|
| — |
|
Cash settled equity |
| — |
|
|
| (13 | ) |
Stock-based compensation |
| 848 |
|
|
| 1,466 |
|
Equity in net income of investee, net of tax |
| (2,025 | ) |
|
| (483 | ) |
Intangible amortization expense |
| 19,901 |
|
|
| 19,490 |
|
COVID-19 related costs, net of grant income |
| — |
|
|
| 471 |
|
Tax effected impact of adjustments |
| (10,154 | ) |
|
| (8,629 | ) |
|
|
|
| ||||
Adjusted net income | $ | 20,201 |
|
| $ | 22,171 |
|
|
|
|
| ||||
Adjusted EPS | $ | 1.42 |
|
| $ | 1.57 |
|
|
|
|
| ||||
Diluted weighted-average number of common shares outstanding |
| 14,193,257 |
|
|
| 14,123,825 |
|
(1) Restructuring and related costs include professional fees for strategic initiatives, organizational consolidation costs, severance and other professional fees. | |||||||
(2) Transaction and integration costs consist of fees incurred related to SOX implementation and business integration efforts. |
Modivcare Inc. Unaudited Key Statistical and Financial Data (in thousands, except for statistical data) | |||||||||||||||||
| Three months ended |
|
|
| Three months ended |
|
| ||||||||||
| March 31, |
| March 31, |
| % |
| December 31, |
| QoQ % | ||||||||
|
|
|
|
|
|
|
|
|
| ||||||||
NEMT Segment |
|
|
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
| ||||||||
Service revenue, net | $ | 469,463 |
|
| $ | 400,920 |
|
| 17.1 | % |
| $ | 458,993 |
|
| 2.3 | % |
Purchased services expense |
| 344,420 |
|
|
| 277,947 |
|
| 23.9 | % |
|
| 331,708 |
|
| 3.8 | % |
Payroll and other expense |
| 63,266 |
|
|
| 54,149 |
|
| 16.8 | % |
|
| 54,938 |
|
| 15.2 | % |
Service expense | $ | 407,686 |
|
| $ | 332,096 |
|
| 22.8 | % |
| $ | 386,646 |
|
| 5.4 | % |
|
|
|
|
|
|
|
|
|
| ||||||||
Gross profit | $ | 61,777 |
|
| $ | 68,824 |
|
| (10.2 | )% |
| $ | 72,347 |
|
| (14.6 | )% |
Gross margin |
| 13.2 | % |
|
| 17.2 | % |
|
|
|
| 15.8 | % |
|
| ||
|
|
|
|
|
|
|
|
|
| ||||||||
G&A expense | $ | 33,875 |
|
| $ | 37,333 |
|
| (9.3 | )% |
| $ | 44,199 |
|
| (23.4 | )% |
G&A expense adjustments: |
|
|
|
|
|
|
|
|
| ||||||||
Restructuring and related costs |
| 7,099 |
|
|
| 5,604 |
|
| 26.7 | % |
|
| 13,869 |
|
| (48.8 | )% |
Transaction and integration costs |
| — |
|
|
| — |
|
| N/M |
|
|
| 4,219 |
|
| — | % |
Settlement related costs |
| 275 |
|
|
| — |
|
| N/M |
|
|
| — |
|
| N/M |
|
Adjusted G&A expense | $ | 26,501 |
|
| $ | 31,729 |
|
| (16.5 | )% |
| $ | 26,111 |
|
| 1.5 | % |
Adjusted G&A expense % of revenue |
| 5.6 | % |
|
| 7.9 | % |
|
|
|
| 5.7 | % |
|
| ||
|
|
|
|
|
|
|
|
|
| ||||||||
Net income | $ | 16,171 |
|
| $ | 17,746 |
|
| (8.9 | )% |
| $ | 17,204 |
|
| (6.0 | )% |
Net income margin |
| 3.4 | % |
|
| 4.4 | % |
|
|
|
| 3.7 | % |
|
| ||
|
|
|
|
|
|
|
|
|
| ||||||||
Adjusted EBITDA | $ | 35,276 |
|
| $ | 37,217 |
|
| (5.2 | )% |
| $ | 46,260 |
|
| (23.7 | )% |
Adjusted EBITDA margin |
| 7.5 | % |
|
| 9.3 | % |
|
|
|
| 10.1 | % |
|
| ||
|
|
|
|
|
|
|
|
|
| ||||||||
Total paid trips (in thousands) |
| 8,202 |
|
|
| 7,111 |
|
| 15.3 | % |
|
| 7,807 |
|
| 5.1 | % |
Average monthly members (in thousands) |
| 33,704 |
|
|
| 32,176 |
|
| 4.7 | % |
|
| 34,819 |
|
| (3.2 | )% |
|
|
|
|
|
|
|
|
|
| ||||||||
Revenue per member per month | $ | 4.64 |
|
| $ | 4.15 |
|
| 11.8 | % |
| $ | 4.39 |
|
| 5.7 | % |
Revenue per trip | $ | 57.24 |
|
| $ | 56.38 |
|
| 1.5 | % |
| $ | 58.79 |
|
| (2.6 | )% |
Monthly utilization |
| 8.1 | % |
|
| 7.4 | % |
|
|
|
| 7.5 | % |
|
| ||
|
|
|
|
|
|
|
|
|
| ||||||||
Purchased services per trip | $ | 41.99 |
|
| $ | 39.09 |
|
| 7.4 | % |
| $ | 42.49 |
|
| (1.2 | )% |
Payroll and other per trip | $ | 7.71 |
|
| $ | 7.61 |
|
| 1.3 | % |
| $ | 7.04 |
|
| 9.5 | % |
Total service expense per trip | $ | 49.70 |
|
| $ | 46.70 |
|
| 6.4 | % |
| $ | 49.53 |
|
| 0.3 | % |
N/M - Not Meaningful. Certain figures in the tables above do not provide meaningful percentage comparison and, thus, the percentage has been removed. |
Modivcare Inc. Unaudited Key Statistical and Financial Data (in thousands, except for statistical data) | |||||||||||||||||
| Three months ended |
|
|
| Three months ended |
|
| ||||||||||
| March 31, |
| March 31, |
| % |
| December 31, |
| QoQ % | ||||||||
|
|
|
|
|
|
|
|
|
| ||||||||
Personal Care Segment |
|
|
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
| ||||||||
Service revenue, net | $ | 174,131 |
|
| $ | 159,698 |
|
| 9.0 | % |
| $ | 176,013 |
|
| (1.1 | )% |
Service expense |
| 136,090 |
|
|
| 122,232 |
|
| 11.3 | % |
|
| 140,642 |
|
| (3.2 | )% |
Gross profit | $ | 38,041 |
|
| $ | 37,466 |
|
| 1.5 | % |
| $ | 35,371 |
|
| 7.5 | % |
Gross Margin |
| 21.8 | % |
|
| 23.5 | % |
|
|
|
| 20.1 | % |
|
| ||
|
|
|
|
|
|
|
|
|
| ||||||||
G&A expense | $ | 22,663 |
|
| $ | 23,133 |
|
| (2.0 | )% |
| $ | 22,829 |
|
| (0.7 | )% |
G&A expense adjustments |
|
|
|
|
|
|
|
|
| ||||||||
Restructuring and related costs |
| — |
|
|
| 181 |
|
| (100.0 | )% |
|
| (6 | ) |
| (100.0 | )% |
Transaction and integration costs |
| 277 |
|
|
| 1,273 |
|
| (78.2 | )% |
|
| 1,216 |
|
| (77.2 | )% |
Stock-based compensation |
| — |
|
|
| 17 |
|
| (100.0 | )% |
|
| — |
|
| N/M |
|
Adjusted G&A expense | $ | 22,386 |
|
| $ | 21,662 |
|
| 3.3 | % |
| $ | 21,619 |
|
| 3.5 | % |
Adjusted G&A expense % of revenue |
| 12.9 | % |
|
| 13.6 | % |
|
|
|
| 12.3 | % |
|
| ||
|
|
|
|
|
|
|
|
|
| ||||||||
Net income | $ | 2,825 |
|
| $ | 1,656 |
|
| 70.6 | % |
| $ | 2,349 |
|
| 20.3 | % |
Net income margin |
| 1.6 | % |
|
| 1.0 | % |
|
|
|
| 1.3 | % |
|
| ||
|
|
|
|
|
|
|
|
|
| ||||||||
Adjusted EBITDA | $ | 17,119 |
|
| $ | 16,621 |
|
| 3.0 | % |
| $ | 16,559 |
|
| 3.4 | % |
Adjusted EBITDA margin |
| 9.8 | % |
|
| 10.4 | % |
|
|
|
| 9.4 | % |
|
| ||
|
|
|
|
|
|
|
|
|
| ||||||||
Total hours (in thousands) |
| 6,824 |
|
|
| 6,535 |
|
| 4.4 | % |
|
| 6,842 |
|
| (0.3 | )% |
Revenue per hour | $ | 25.52 |
|
| $ | 24.44 |
|
| 4.4 | % |
| $ | 25.73 |
|
| (0.8 | )% |
Service expense per hour | $ | 19.94 |
|
| $ | 18.70 |
|
| 6.6 | % |
| $ | 20.56 |
|
| (3.0 | )% |
N/M - Not Meaningful. Certain figures in the tables above do not provide meaningful percentage comparison and, thus, the percentage has been removed. |
Modivcare Inc. Unaudited Key Statistical and Financial Data (in thousands, except for statistical data) | |||||||||||||||||
| Three months ended |
|
|
| Three months ended |
|
| ||||||||||
| March 31, |
| March 31, |
| % |
| December 31, |
| QoQ % | ||||||||
|
|
|
|
|
|
|
|
|
| ||||||||
RPM Segment |
|
|
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
| ||||||||
Service revenue, net | $ | 18,712 |
|
| $ | 13,857 |
|
| 35.0 | % |
| $ | 18,915 |
|
| (1.1 | )% |
Service expense |
| 6,490 |
|
|
| 4,987 |
|
| 30.1 | % |
|
| 6,678 |
|
| (2.8 | )% |
Gross profit | $ | 12,222 |
|
| $ | 8,870 |
|
| 37.8 | % |
| $ | 12,237 |
|
| (0.1 | )% |
Gross Margin |
| 65.3 | % |
|
| 64.0 | % |
|
|
|
| 64.7 | % |
|
| ||
|
|
|
|
|
|
|
|
|
| ||||||||
G&A expense | $ | 5,769 |
|
| $ | 4,962 |
|
| 16.3 | % |
| $ | 5,636 |
|
| 2.4 | % |
G&A expense adjustments |
|
|
|
|
|
|
|
|
| ||||||||
Restructuring and related costs |
| — |
|
|
| 24 |
|
| (100.0 | )% |
|
| — |
|
| N/M |
|
Transaction and integration costs |
| 32 |
|
|
| 647 |
|
| (95.1 | )% |
|
| 174 |
|
| (81.6 | )% |
Stock-based compensation |
| — |
|
|
| 29 |
|
| (100.0 | )% |
|
| — |
|
| N/M |
|
Adjusted G&A expense | $ | 5,737 |
|
| $ | 4,262 |
|
| 34.6 | % |
| $ | 5,462 |
|
| 5.0 | % |
Adjusted G&A expense % of revenue |
| 30.7 | % |
|
| 30.8 | % |
|
|
|
| 28.9 | % |
|
| ||
|
|
|
|
|
|
|
|
|
| ||||||||
Net income (loss) | $ | 429 |
|
| $ | (162 | ) |
| N/M |
|
| $ | 672 |
|
| (36.2 | )% |
Net income (loss) margin |
| 2.3 | % |
|
| (1.2 | )% |
|
|
|
| 3.6 | % |
|
| ||
|
|
|
|
|
|
|
|
|
| ||||||||
Adjusted EBITDA | $ | 6,485 |
|
| $ | 4,608 |
|
| 40.7 | % |
| $ | 6,775 |
|
| (4.3 | )% |
Adjusted EBITDA margin |
| 34.7 | % |
|
| 33.3 | % |
|
|
|
| 35.8 | % |
|
| ||
|
|
|
|
|
|
|
|
|
| ||||||||
Average monthly members (in thousands) |
| 235 |
|
|
| 169 |
|
| 39.1 | % |
|
| 236 |
|
| (0.4 | )% |
Revenue per member per month | $ | 26.54 |
|
| $ | 27.33 |
|
| (2.9 | )% |
| $ | 26.72 |
|
| (0.7 | )% |
Service expense per member per month | $ | 9.21 |
|
| $ | 9.84 |
|
| (6.4 | )% |
| $ | 9.43 |
|
| (2.3 | )% |
N/M - Not Meaningful. Certain figures in the tables above do not provide meaningful percentage comparison and, thus, the percentage has been removed. |
Modivcare Inc. Unaudited Key Statistical and Financial Data (in thousands) | |||||||||||||||||
| Three months ended |
|
|
| Three months ended |
|
| ||||||||||
| March 31, |
| March 31, |
| % |
| December 31, |
| QoQ % | ||||||||
|
|
|
|
|
|
|
|
|
| ||||||||
Corporate and Other Segment |
|
|
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
| ||||||||
G&A expense | $ | 17,406 |
|
| $ | 11,380 |
|
| 53.0 | % |
| $ | 17,399 |
|
| — | % |
G&A expense adjustments |
|
|
|
|
|
|
|
|
| ||||||||
Restructuring and related costs |
| 7,346 |
|
|
| 31 |
|
| N/M |
|
|
| — |
|
| N/M |
|
Transaction and integration costs |
| 564 |
|
|
| 1,791 |
|
| (68.5 | )% |
|
| 2,050 |
|
| (72.5 | )% |
Settlement related costs |
| — |
|
|
| — |
|
| N/M |
|
|
| 3,564 |
|
| (100.0 | )% |
Cash settled equity |
| — |
|
|
| (13 | ) |
| (100.0 | )% |
|
| 19 |
|
| (100.0 | )% |
Stock-based compensation |
| 848 |
|
|
| 1,420 |
|
| (40.3 | )% |
|
| 1,823 |
|
| (53.5 | )% |
Adjusted G&A expense | $ | 8,648 |
|
| $ | 8,151 |
|
| 6.1 | % |
| $ | 9,943 |
|
| (13.0 | )% |
Adjusted G&A expense % of consolidated revenue |
| 1.3 | % |
|
| 1.4 | % |
|
|
|
| 1.5 | % |
|
|
| Three months ended |
|
|
| Three months ended |
|
| ||||||||||
| March 31, |
| March 31, |
| % |
| December 31, |
| QoQ % | ||||||||
|
|
|
|
|
|
|
|
|
| ||||||||
Consolidated Modivcare |
|
|
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
| ||||||||
G&A expense | $ | 79,713 |
|
| $ | 76,808 |
|
| 3.8 | % |
| $ | 90,063 |
|
| (11.5 | )% |
G&A expense adjustments |
|
|
|
|
|
|
|
|
| ||||||||
Restructuring and related costs |
| 14,445 |
|
|
| 5,840 |
|
| 147.3 | % |
|
| 13,863 |
|
| 4.2 | % |
Transaction and integration costs |
| 873 |
|
|
| 3,711 |
|
| (76.5 | )% |
|
| 7,659 |
|
| (88.6 | )% |
Settlement related costs |
| 275 |
|
|
| — |
|
| N/M |
|
|
| 3,564 |
|
| (92.3 | )% |
Cash settled equity |
| — |
|
|
| (13 | ) |
| (100.0 | )% |
|
| 19 |
|
| (100.0 | )% |
Stock-based compensation |
| 848 |
|
|
| 1,466 |
|
| (42.2 | )% |
|
| 1,823 |
|
| (53.5 | )% |
Adjusted G&A expense | $ | 63,272 |
|
| $ | 65,804 |
|
| (3.8 | )% |
| $ | 63,135 |
|
| 0.2 | % |
Adjusted G&A expense % of revenue |
| 9.6 | % |
|
| 11.5 | % |
|
|
|
| 9.7 | % |
|
| ||
N/M - Not Meaningful. Certain figures in the tables above do not provide meaningful percentage comparison and, thus, the percentage has been removed. |
Last Trade: | US$16.31 |
Daily Change: | 0.72 4.62 |
Daily Volume: | 167,880 |
Market Cap: | US$232.250M |
October 23, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB